Five Below Inc vs Twist Bioscience Corp — how do they compare? Five Below Inc trades at $209.72 (market cap $11.25B), while Twist Bioscience Corp trades at $157.11 (market cap $10.32B). The key difference: Five Below Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Twist Bioscience Corp for 27 Days on average.
| FIVE | TWST | |
|---|---|---|
Market Cap | $11.25B | $10.32B |
Volume | 986,546 | 5,894,998 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $205.00 |
52-Week Low | $138.49 | $25.45 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | $12.10B | $10.24B |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $209.56, down 0.17% on the day, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 40.26% gross margins and 28.25% ROE, though net margins declined to 6.54% in 2025. Recent earnings beats and a raised 2026 outlook highlight growth momentum, supported by store expansion and digital initiatives. Cash flow improved significantly in 2025 with $152M net inflow after two years of negative flows.
The stock offers substantial upside to the $298.44 consensus target, with 60% analyst buy ratings and no sell recommendations. Key risks include premium valuation (P/E 18.32) and execution pressure amid consumer spending concerns. Growth catalysts include the $600M buyback and store revamp strategy, though technical resistance near $212 may limit near-term gains.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →